Table 4 Univariate analysis of responders versus non-responders at 6 months based on the median of the change of day-time systolic ABP
From: Skin sodium content as a predictor of blood pressure response to renal denervation
Baseline | ||||
|---|---|---|---|---|
Median ≤ −12 mmHg | Median > −12 mmHg | P value | P value* | |
Responder (n = 27) | Non-Responder (n = 26) | |||
Change of day-time systolic BP at 6 months (mmHg) | −19.7 ± 7.6 | 1.8 ± 9.1 | <0.001 | <0.001 |
Baseline characteristics | ||||
BMI (kg/m2) | 30.7 ± 4.2 | 29.3 ± 3.7 | 0.182 | 0.392 |
Gender (m/w) | 0.389 | 0.256 | ||
Age (years) | 59.5 ± 10.1 | 63.7 ± 8.2 | 0.106 | 0.089 |
Na-MRI | ||||
Sodium in M. triceps surae (AU) | 19.5 ± 3.0 | 21.6 ± 5.5 | 0.074 | 0.081 |
Sodium in skin (AU) | 19.6 ± 2.6 | 22.4 ± 5.4 | 0.021 | 0.015 |
Baseline office BP | ||||
Systolic BP (mmHg) | 152.4 ± 17.4 | 156 ± 22.8 | 0.481 | |
Diastolic BP (mmHg) | 87.1 ± 16.3 | 84.7 ± 12.9 | 0.550 | |
Heart rate (bpm) | 73.2 ± 14.5 | 65.6 ± 13.3 | 0.056 | 0.150 |
Baseline ABP | ||||
24-h systolic BP (mmHg) | 159.8 ± 13.5 | 150.8 ± 14.5 | 0.023 | |
24-h diastolic BP (mmHg) | 89.2 ± 12.1 | 83.6 ± 11.0 | 0.081 | |
24-h heart rate (bpm) | 70.5 ± 12.1 | 63.0 ± 9.2 | 0.019 | 0.025 |
Systolic day-time BP (mmHg) | 162.5 ± 13.8 | 152.8 ± 13.9 | 0.014 | |
Diastolic day-time BP (mmHg) | 91.9 ± 12.1 | 86.1 ± 11.2 | 0.074 | |
Heart rate day-time (bpm) | 71.8 ± 12.0 | 64.5 ± 9.6 | 0.025 | 0.030 |
Systolic night-time BP (mmHg) | 153.6 ± 19.8 | 145.3 ± 22.1 | 0.153 | |
Diastolic night-time BP (mmHg) | 82.6 ± 13.4 | 77.5 ± 13.0 | 0.159 | |
Night-time heart rate (bpm) | 66.1 ± 12.2 | 58.1 ± 8.2 | 0.010 | 0.012 |
Laboratory values | ||||
Hematocrit (%) | 40.9 ± 4.1 | 40.7 ± 4.9 | 0.883 | 0.759 |
Triglyceride | 233.6 ± 119.2 | 76.7 ± 104.7 | 0.071 | 0.071 |
Cholesterol (mg/dl) | 204.3 ± 43.9 | 189.4 ± 58.7 | 0.299 | 0.286 |
LDL-cholesterol (mg/dl) | 140.6 ± 36.0 | 125.0 ± 46.4 | 0.178 | 0.161 |
Antihypertensive medication | ||||
Diuretics, n (%) | 24 (88.9) | 25 (96.2) | 0.317 | 0.432 |
Aldosterone-antagonist, n (%) | 7 (25.9) | 1 (3.8) | 0.025 | 0.036 |
ACE inhibitors, n (%) | 10 (37.0) | 9 (34.6) | 0.854 | 0.583 |
ARBs, n (%) | 21 (77.8) | 21 (80.8) | 0.788 | 0.681 |
Direct renin inhibitors, n (%) | 14 (51.9) | 8 (30.8) | 0.119 | 0.201 |
Betablockers, n (%) | 20 (74.1) | 22 (84.6) | 0.344 | 0.596 |
Calcium-channel blockers, n (%) | 23 (85.2) | 22 (84.6) | 0.954 | 0.961 |
Vasodilators, n (%) | 11 (40.7) | 8 (30.8) | 0.449 | 0.619 |
Centrally acting sympatholytics, n (%) | 21 (77.8) | 20 (76.9) | 0.941 | 0.746 |
